Skip to contentC
Cumberland Pharmaceuticals Inc
C
CPIXCumberland Pharmaceuticals Inc Q4 2025 · 10-K
Revenue$13.68M$13.68M+31.1% vs Q4 2024 Net Income-$1.41M-$1.41MN/M vs Q4 2024 EPS Diluted-$0.09-$0.09N/M vs Q4 2024 Operating Income-$1,371,202N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cumberland Pharmaceuticals Inc · CIK 1087294 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$3,025−99.8% Margins · derivedOperating margin-10.0%+7.6 pt vs Q4 2024
Net margin-10.3%+7.9 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 9, 2026 · 68 d after period end